诺思兰德

NL005 动物实验及II期临床研究论文

https://academic.oup.com/cardiovascres/advance-article/doi/10.1093/cvr/cvaf223/8322149

Cardiovascular Research(2025)00,1–12 https://doi.org/10.1093/cvr/cvaf223

 

塞多明基注射液治疗Rutherford 5级严重下肢缺血Ⅲ期临床试验（HOPE CLTI-2）论文

Seltoplasmid promotes ulcer healing versus placebo for treating patients with chronic limb-threatening ischemia: HOPE CLTI-2 trial

 Molecular Therapy. 2025 Apr 11:S1525-0016(25)00283-7. 

 

重组人肝细胞生长因子裸质粒治疗慢性缺血性疾病作用机制及注射位点选择的研究

Optimal injection sites for therapeutic angiogenesis: HGF-mediated regulation of HIF-1α via MAPK/PI3K pathways in hypoxic endothelial cells

Tissue and Cell (2025), doi: https://doi.org/10.1016/j.tice.2025.102871.

 

重组人肝细胞生长因子裸质粒治疗慢性缺血性疾病的系统评价与Meta分析

Recombinant Human Hepatocyte Growth Factor Plasmids for Treating Patients with Chronic Limb Threatening Ischaemia: A Systematic Review and Meta-analysis

European Journalof Vascular&EndovascularSurgery (2024)

https://doi.org/10.1016/j.ejvs.2024.07.016.

 

NL003II期临床试验长期随访结果论文

Nine-year follow-up of patients receiving recombinant human hepatocyte growth factor nude plasmid DNA for critical limb ischemia: Updated safety and efficacy results

Vascular Investigation and Therapy（ISSN:2589-9686) DOI:10.4103/vit_21_24

 

NL003 III期临床试验方案论文

Rationale and design for the study of recombinant human hepatocyte growth factor plasmid in the treatment of patients with chronic limb-threatening ischemia (HOPE CLTI): Randomized, placebo-controlled, double-blind, phase III clinical trials

American heart journal, vol. 2022 Aug 21;254:88-101.

 

NL003 II期临床试验论文

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia

Molecular Therapy. 2019 Dec 4;27(12):2158-2165.

 

NL003 I期临床试验论文

A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia.

The Journal of Gene Medicine. 2011 Nov;13(11):602-10.

 

NL005 I期临床试验论文

A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers

 Journal of Cellular and Molecular Medicine. 2021 Aug 4.doi: 10.1111/jcmm.16693.

  

友情链接：百度  | 诺思兰德

联系方式

地 址：北京市海淀区上地开拓路5号中关村生物医药园A406

热 线：010-82890893

邮 箱：northland@northland-bio.com

网 址：www.northland-bio.com

不良报告电话：010-82890893-8031

不良报告邮箱：pv@northland-bio.com

在线留言

请留下您的宝贵意见或建议及联系方式（邮箱或电话），方便我们能及时回复您！

安全验证
确认
%{tishi_zhanwei}%

北京诺思兰德生物技术股份有限公司

一家专业从事基因治疗药物、重组蛋白质类药物和眼科用药物研发、生产及销售的创新型生物制药企业。

手机版网站

手机版网站

下肢缺血科学研究

下肢缺血科学研究

心梗科学研究

心梗科学研究

营业执照

网站建设：中企动力 北京